

Nana-Goar V Pogosova

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4390341/publications.pdf>

Version: 2024-02-01

40
papers

9,193
citations

304743

22
h-index

182427

51
g-index

53
all docs

53
docs citations

53
times ranked

12604
citing authors

#	ARTICLE	IF	CITATIONS
1	Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. New England Journal of Medicine, 2017, 377, 1319-1330.	27.0	1,745
2	Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet, The, 2019, 394, 121-130.	13.7	1,625
3	Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. Lancet, The, 2016, 388, 761-775.	13.7	1,414
4	EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. European Journal of Preventive Cardiology, 2016, 23, 636-648.	1.8	772
5	Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet, The, 2018, 391, 219-229.	13.7	651
6	Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. European Journal of Preventive Cardiology, 2019, 26, 824-835.	1.8	558
7	Secondary prevention in the clinical management of patients with cardiovascular diseases. Core components, standards and outcome measures for referral and delivery. European Journal of Preventive Cardiology, 2014, 21, 664-681.	1.8	486
8	Cardiac rehabilitation in Europe: results from the European Cardiac Rehabilitation Inventory Survey. European Journal of Cardiovascular Prevention and Rehabilitation, 2010, 17, 410-418.	2.8	403
9	Psychosocial aspects in cardiac rehabilitation: From theory to practice. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation of the European Society of Cardiology. European Journal of Preventive Cardiology, 2015, 22, 1290-1306.	1.8	227
10	Design and baseline characteristics of participants in the <sc>Researching cardiovascular </sc>events with a <sc>Weekly </sc> <sc>IN</sc>cretin in <sc>D</sc>iabetes (<sc>REWIND</sc>) trial on the cardiovascular effects of dulaglutide. Diabetes, Obesity and Metabolism, 2018, 20, 42-49.	4.4	160
11	Lifestyle and risk factor management in people at high risk of cardiovascular disease. A report from the European Society of Cardiology European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) IV cross-sectional survey in 14 European regions. European Journal of Preventive Cardiology, 2016, 23, 2007-2018.	1.8	153
12	Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. Canadian Journal of Cardiology, 2017, 33, 1027-1035.	1.7	133
13	Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology. Cardiovascular Diabetology, 2015, 14, 133.	6.8	101
14	Practice patterns and outcomes after stroke across countries at different economic levels (INTERSTROKE): an international observational study. Lancet, The, 2018, 391, 2019-2027.	13.7	96
15	Psychosocial risk factors in relation to other cardiovascular risk factors in coronary heart disease: Results from the EUROASPIRE IV survey. A registry from the European Society of Cardiology. European Journal of Preventive Cardiology, 2017, 24, 1371-1380.	1.8	94
16	Primary prevention efforts are poorly developed in people at high cardiovascular risk: A report from the European Society of Cardiology EURObservational Research Programme EUROASPIRE V survey in 16 European countries. European Journal of Preventive Cardiology, 2021, 28, 370-379.	1.8	83
17	Exercise-based cardiac rehabilitation in twelve European countries results of the European cardiac rehabilitation registry. International Journal of Cardiology, 2017, 228, 58-67.	1.7	70
18	Assessing the Global Burden of Ischemic Heart Disease: Part 1: Methods for a Systematic Review of the Global Epidemiology of Ischemic Heart Disease in 1990 and 2010. Global Heart, 2012, 7, 315.	2.3	63

#	ARTICLE	IF	CITATIONS
19	Simplifying the audit of risk factor recording and control: A report from an international study in 11 countries. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 1202-1210.	1.8	42
20	Poor adherence to lifestyle recommendations in patients with coronary heart disease: results from the EUROASPIRE surveys. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 383-395.	1.8	40
21	Prediction of recurrent event in patients with coronary heart disease: the EUROASPIRE Risk Model. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 328-339.	1.8	27
22	Ischaemic heart disease in the former Soviet Union 1990â€“2015 according to the Global Burden of Disease 2015 Study. <i>Heart</i> , 2018, 104, 58-66.	2.9	26
23	Cost-effectiveness of optimized adherence to prevention guidelines in European patients with coronary heart disease: Results from the EUROASPIRE IV survey. <i>International Journal of Cardiology</i> , 2018, 272, 20-25.	1.7	24
24	Incidence of cardiovascular events in patients with stabilized coronary heart disease: the EUROASPIRE IV follow-up study. <i>European Journal of Epidemiology</i> , 2019, 34, 247-258.	5.7	22
25	Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin. <i>European Heart Journal</i> , 2021, 42, 2565-2573.	2.2	17
26	Can level of education, accreditation and use of databases in cardiac rehabilitation be improved? Results from the European Cardiac Rehabilitation Inventory Survey. <i>European Journal of Preventive Cardiology</i> , 2012, 19, 143-150.	1.8	14
27	The use of HeartQoL in patients with coronary heart disease: Association with risk factors and European reference values. The EUROASPIRE IV study of the European Society of Cardiology. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 1174-1186.	1.8	14
28	Anger or emotional upset and heavy physical exertion as triggers of stroke: the INTERSTROKE study. <i>European Heart Journal</i> , 2022, 43, 202-209.	2.2	14
29	Sequelae of COVID-19 at long-term follow-up after hospitalization. <i>Rational Pharmacotherapy in Cardiology</i> , 2022, 18, 118-126.	0.8	13
30	Secondary prevention in patients with coronary artery disease in Russia and Europe: results from the Russian part of the EUROASPIRE V survey. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2020, 19, 2739.	1.4	9
31	Governmental efforts for cardiovascular disease prevention efforts in the Russian Federation. <i>Cardiovascular Diagnosis and Therapy</i> , 2017, 67, S48-S54.	1.7	8
32	Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 786-795.	3.0	6
33	Hypertensives in Russia are interested in a healthier lifestyle: results of the RELIF multicenter study. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2011, 18, 224-232.	2.8	5
34	Potential for optimizing management of obesity in the secondary prevention of coronary heart disease. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021, , .	4.0	5
35	Costs associated with cardiovascular disease create a significant burden for society and they seem to be globally underestimated. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 1147-1149.	1.8	3
36	Alcohol consumption patterns across Europe and adherence to the European guidelines in coronary patients: Findings from the ESC-EORP EUROASPIRE V survey. <i>Atherosclerosis</i> , 2020, 313, 35-42.	0.8	3

#	ARTICLE	IF	CITATIONS
37	Pharmacoeconomic study of rivaroxaban and acetylsalicylic acid combination use in patients with coronary artery disease and/or peripheral artery disease. Russian Journal of Cardiology, 2019, , 76-86.	1.4	2
38	New treatments and technologies in cardiac rehabilitation programs. Voprosy Kurortologii, Fizioterapii, i Lechebnoi Fizicheskoi Kultury, 2022, 99, 50.	0.5	1
39	Factors affecting the uptake of national practice guidelines by physicians treating common CVDS in out-patient settings. Kardiologiya, 2022, 62, 33-44.	0.7	1
40	Social Network-Based Digital Stroke Prevention: Opportunities, Results and Prospects. Rational Pharmacotherapy in Cardiology, 2021, 17, 696-701.	0.8	0